Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions

Abstract

The use of amivantamab-chemotherapy resulted in superior efficacy as compared with chemotherapy alone as first-line treatment of patients with advanced NSCLC with <i>EGFR</i> exon 20 insertions. (Funded by Janssen Research and Development; PAPILLON ClinicalTrials.gov number, NCT04538664.).